ARS Pharmaceuticals hit with surprise FDA rejection of Neffy, its nasal spray epinephrine alternative
Fierce Pharma
SEPTEMBER 20, 2023
ARS Pharmaceuticals learned that lesson the hard way, as the FDA issued a surprise rejection of its anaphylaxis nasal spray Neffy. Positive FDA advisory committee votes aren’t always a blueprint for approval. Positive FDA advisory committee votes aren’t always a blueprint for approval.
Let's personalize your content